Moleculin Biotech (MBRX) has provided an update.
Moleculin Biotech, Inc. has released promising interim data for Annamycin in its ongoing AML (Acute Myeloid Leukemia) clinical program. This positive news was shared during a press release and will be further discussed in a virtual AML Clinical Day event that the company is hosting, aiming to provide investors and interested parties with more insights into the drug’s development and potential impact on the market.
Find detailed analytics on MBRX stock on TipRanks’ Stock Analysis page.
